Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HALO
stocks logo

HALO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
398.22M
+33.63%
1.895
+50.4%
377.29M
+42.45%
1.740
+56.76%
404.82M
+24.28%
1.887
+22.56%
Estimates Revision
The market is revising Upward the revenue expectations for Halozyme Therapeutics, Inc. (HALO) for FY2025, with the revenue forecasts being adjusted by 1.71% over the past three months. During the same period, the stock price has changed by -15.99%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.71%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.41%
In Past 3 Month
Stock Price
Go Down
down Image
-15.99%
In Past 3 Month
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 77.63 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 77.63 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 62.950
sliders
Low
56.00
Averages
77.63
High
92.00
Current: 62.950
sliders
Low
56.00
Averages
77.63
High
92.00
Goldman Sachs
Neutral -> Sell
downgrade
$56
2025-12-04
New
Reason
Goldman Sachs
Price Target
$56
2025-12-04
New
downgrade
Neutral -> Sell
Reason
Goldman Sachs downgraded Halozyme to Sell from Neutral with a $56 price target. A central debate for Halozyme is the long-term value of its Enhanze royalty model, which faces a substantial post-2030 revenue cliff as roughly 70% of royalties roll off contract between 2030-2035 and appears unlikely to be offset through typical business-development pacing, the analyst tells investors in a research note. Current valuation implies a terminal value that assumes roughly $34B in new partner product revenue by 2041, a level that seems achievable only under optimistic scenarios despite the recent Elektrofi acquisition, the firm says.
Goldman Sachs
Neutral
maintain
$54 -> $56
2025-11-18
Reason
Goldman Sachs
Price Target
$54 -> $56
2025-11-18
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Halozyme to $56 from $54 and keeps a Neutral rating on the shares. Halozyme announced a global non-exclusive collaboration and license agreement with Merus to use Halozyme's Enhanze technology in the development of a subcutaneous formulation of petosemtamab, the analyst tells investors in a research note. While strategically positive, Goldman doesn't expect the announcement to meaningfully move the stock.
Citizens JMP
Outperform
maintain
$91 -> $92
2025-11-04
Reason
Citizens JMP
Price Target
$91 -> $92
2025-11-04
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Halozyme to $92 from $91 and keeps an Outperform rating on the shares. Halozyme reported a strong quarter driven by indication and global expansion of ENHANZE partnered products, the analyst tells investors in a research note. The firm expects Halozyme to achieve 2026 EBITDA of more than $1B, a milestone it would reach a year ahead of prior long-term guidance.
JPMorgan
Jessica Fye
Neutral
maintain
$63 -> $65
2025-10-27
Reason
JPMorgan
Jessica Fye
Price Target
$63 -> $65
2025-10-27
maintain
Neutral
Reason
JPMorgan analyst Jessica Fye raised the firm's price target on Halozyme to $65 from $63 and keeps a Neutral rating on the shares. The firm updated the company's model ahead of the Q3 report.
Morgan Stanley
Overweight
downgrade
$80 -> $79
2025-10-20
Reason
Morgan Stanley
Price Target
$80 -> $79
2025-10-20
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Halozyme to $79 from $80 and keeps an Overweight rating on the shares. Halozyme has not yet scheduled a date to report Q3 earnings, but the firm continues to believe that strength in royalties and cost discipline will drive EPS outperformance for the remainder of 2025, the analyst tells investors.
Leerink
David Risinger
Underperform -> Market Perform
upgrade
2025-10-14
Reason
Leerink
David Risinger
Price Target
2025-10-14
upgrade
Underperform -> Market Perform
Reason
Leerink analyst David Risinger upgraded Halozyme to Market Perform from Underperform.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Halozyme Therapeutics Inc (HALO.O) is 8.45, compared to its 5-year average forward P/E of 14.89. For a more detailed relative valuation and DCF analysis to assess Halozyme Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
14.89
Current PE
8.45
Overvalued PE
19.66
Undervalued PE
10.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
13.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
18.26
Undervalued EV/EBITDA
9.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.66
Current PS
0.00
Overvalued PS
10.71
Undervalued PS
4.61
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 4215.85% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HALO News & Events

Events Timeline

(ET)
2025-12-04
13:30:00
Halozyme Secures Preliminary Injunction Against Merck's Keytruda SC Sales in Germany
select
2025-11-17 (ET)
2025-11-17
07:05:10
Merus and Halozyme Form Partnership and Licensing Deal for Petosemtamab
select
2025-11-07 (ET)
2025-11-07
08:33:04
Halozyme: JNJ Receives FDA Approval for New Use of DARZALEX Faspro
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
05:00 AMNASDAQ.COM
Stocks Close with Mixed Results Amid Rising Bond Yields

  • Market Performance: The S&P 500 closed up by +0.11%, reaching a 3-week high, while the Dow and Nasdaq experienced slight declines due to rising bond yields and mixed corporate earnings reports.

  • Economic Indicators: Initial jobless claims fell to a 3-year low, indicating a stronger labor market, while factory orders rose by +0.2%, slightly below expectations.

  • Corporate Earnings: Q3 earnings season showed strong results, with 83% of S&P 500 companies exceeding forecasts, leading to a +14.6% increase in earnings, significantly above the expected +7.2%.

  • Interest Rates and Global Markets: Rising U.S. Treasury yields were influenced by expectations of a Bank of Japan rate hike, while European bond yields were mixed, reflecting varied economic conditions across regions.

[object Object]
Preview
7.0
03:13 AMNewsfilter
Halozyme Secures Preliminary Injunction Against Merck's Keytruda SC in Germany
  • Patent Protection Victory: The Munich Regional Court ruled in favor of Halozyme's MDASE™ patent, granting a preliminary injunction that requires Merck to cease distribution of Keytruda SC in Germany, which is expected to effectively protect Halozyme's market share.
  • Market Impact: This injunction will directly affect Merck's launch activities for Keytruda SC in Germany; although Merck may appeal, Halozyme is confident in the injunction's validity, potentially extending its market exclusivity.
  • Global Litigation Strategy: The lawsuit in Germany is part of Halozyme's global patent enforcement strategy, with additional litigation in the U.S. alleging that Merck's Keytruda SC infringes 15 patents, demonstrating Halozyme's firm stance on intellectual property protection.
  • Patient Choice Assurance: Despite the injunction on Keytruda SC, patients will still have access to the IV version of Keytruda, ensuring treatment options remain unaffected while highlighting Halozyme's innovative capabilities in drug delivery technology.
[object Object]
Preview
7.0
02:42 AMPRnewswire
Halozyme Secures Preliminary Injunction Against Merck's Keytruda SC in Germany
  • Patent Protection Victory: The Munich Regional Court ruled in favor of Halozyme's MDASE™ patent, granting a preliminary injunction that requires Merck to cease distribution of Keytruda SC in Germany, thereby strengthening Halozyme's market competitiveness through robust intellectual property protection.
  • Market Impact: This injunction directly affects Merck's launch activities for Keytruda SC in Germany; although the decision is appealable, Halozyme is confident in the validity of its patent, which could lead to significant market losses for Merck if upheld.
  • Global Litigation Strategy: The lawsuit in Germany is part of Halozyme's broader global enforcement strategy against Merck, with additional patent infringement claims filed in the U.S. alleging that Merck's Keytruda SC infringes 15 of Halozyme's patents, demonstrating its commitment to defending its intellectual property worldwide.
  • Patient Choice Assurance: Despite the restrictions on Keytruda SC sales, patients will still have access to the IV version of Keytruda, ensuring that treatment options remain available, which also highlights Halozyme's innovative capabilities in drug delivery technology.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Halozyme Therapeutics Inc (HALO) stock price today?

The current price of HALO is 62.95 USD — it has decreased -2.64 % in the last trading day.

arrow icon

What is Halozyme Therapeutics Inc (HALO)'s business?

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

arrow icon

What is the price predicton of HALO Stock?

Wall Street analysts forecast HALO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HALO is 77.63 USD with a low forecast of 56.00 USD and a high forecast of 92.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Halozyme Therapeutics Inc (HALO)'s revenue for the last quarter?

Halozyme Therapeutics Inc revenue for the last quarter amounts to 354.26M USD, increased 22.12 % YoY.

arrow icon

What is Halozyme Therapeutics Inc (HALO)'s earnings per share (EPS) for the last quarter?

Halozyme Therapeutics Inc. EPS for the last quarter amounts to 1.43 USD, increased 36.19 % YoY.

arrow icon

What changes have occurred in the market's expectations for Halozyme Therapeutics Inc (HALO)'s fundamentals?

The market is revising Upward the revenue expectations for Halozyme Therapeutics, Inc. (HALO) for FY2025, with the revenue forecasts being adjusted by 1.71% over the past three months. During the same period, the stock price has changed by -15.99%.
arrow icon

How many employees does Halozyme Therapeutics Inc (HALO). have?

Halozyme Therapeutics Inc (HALO) has 350 emplpoyees as of December 05 2025.

arrow icon

What is Halozyme Therapeutics Inc (HALO) market cap?

Today HALO has the market capitalization of 7.40B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free